I am Genotype AS and have not been in any hospital for 30 years, or for as long as I can remember, to be treated for malaria fever. I am bitten my mosquitoes every day. If you put my resilience to not ...

And GSK’s first-to-market Arexvy lived up to that expectation with $1.5 billion sales in its first year of commercialization. Related As RSV vaccine clash kicks off, GSK sues Pfizer for patent ...

GSK’s share price has fallen a long way from its one-year high, which has only increased the major undervaluation I’d seen in the stock before that. When investing, your capital is at risk ...

GSK has reached an agreement that it says will resolve 93% of the outstanding lawsuits brought against the company claiming that its gastrointestinal drug Zantac caused cancer. The company has ...

British drugs firm GSK has been accused of burying a report said to prove a link between its medication Zantac and cancer, a new lawsuit has claimed. A pension fund has filed a class action ...

GSK has garnered FDA approval for its pentavalent meningococcal vaccine Penmenvy, tipped as one of its major launches for 2025 and a rival to Pfizer's first-to-market Penbraya. The shot protects ...

WorldAtlas published a list of South Dakota's best retirement towns, with a focus on affordability, community support, and safety. The list heavily favored towns in eastern South Dakota, with ...

The UK's two largest drug makers, Cambridge-based AstraZeneca and London-headquartered GSK, are among the jewels in the British economy with a combined value of £237billion. Both companies rely ...

Shares in GSK (GlaxoSmithKline), AstraZeneca and Haleon all climbed in value on Thursday as a result. GSK shares were 3.4% higher, AstraZeneca was up 2.6% and Sensodyne maker Haleon was up 1.9%.